Cyprumed and MSD Enter Licensing Agreement for Oral Peptide Therapeutics

Cyprumed, a drug delivery technology company based in Innsbruck, Austria, and the pharmaceutical company MSD (Merck & Co. in the US and Canada) announce that the two companies have signed a non-exclusive license and option agreement to develop oral formulations of MSD peptides using Cyprumed's innovative drug delivery technology.

Under the terms of the agreement, MSD receives non-exclusive worldwide rights to Cyprumed's oral peptide delivery platform for an undisclosed number of targets. The agreement also grants MSD the option to exclusively license Cyprumed's technology for the use of individual receptor targets. Cyprumed is eligible to receive up to $493 million in upfront payments, development, regulatory and net sales milestones related to the approval of any products developed under the collaboration. In addition, Cyprumed will receive further potential payments if MSD exercises its option for an exclusive license. Under the terms of the agreement, MSD is responsible for the research, development, manufacturing and commercialization of all products using Cyprumed's drug delivery technology.

“This collaboration with MSD, a company dedicated to peptide therapeutics, marks a significant step for Cyprumed. Our drug delivery technology, with its proven effectiveness and scalability, has the potential to unlock new opportunities in peptide therapeutics. Continuing this collaboration with MSD to develop our innovative tablet formulations for additional targets is a great validation of our technology,” said Florian Föger, CEO of Cyprumed.

“We look forward to collaborating with the Cyprumed team to leverage their technology to help advance our macrocyclic peptide development efforts,” said Allen C. Templeton, Vice President, Pharmaceutical Sciences, MSD Research Laboratories.